ArticleSurgical neurology international2025
The role of malondialdehyde as a biomarker for predicting adverse outcomes in severe and moderate traumatic brain injury patients with subarachnoid hemorrhage.
Article in Surgical neurology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Traumatic brain injury (TBI) remains a leading cause of death and disability, particularly in younger populations, with significant clinical and socioeconomic burdens in both developed and developing countries. Despite extensive research, outcomes for TBI patients, especially those with subarachnoid hemorrhage (SAH), remain poor. Oxidative stress and ischemia, both typical sequelae of TBI, contribute to secondary brain injury, which worsens clinical outcomes. SAH exacerbates brain damage by degrading hemoglobin, forming oxyhemoglobin, and increasing oxidative stress. This cascade ultimately leads to lipid peroxidation, with malondialdehyde (MDA) as a key product. This study aims to evaluate the potential of elevated MDA levels as a prognostic biomarker for predicting poor clinical outcomes in patients with moderate-to-severe TBI complicated by SAH. Methods: This prospective cohort study included patients with moderate to severe TBI and SAH who were evaluated at RSUP Prof. Dr. I.G.N.G. Ngoerah Denpasar, Bali, Indonesia from January to June 2024. Serum MDA levels were tested at admission and classed as high or low using receiver operating characteristic (ROC) curve analysis. Additional clinical characteristics, such as demographic information and clinical condition, were also collected. Fifty-eight patients were followed for 3 months to determine clinical results, which were divided into two categories: good and poor. ROC curve analysis, descriptive statistics, proportion comparisons, and Cox regression were all performed using IBM Statistical Package for the Social Sciences version 26. Results: Patients with high MDA levels had a significantly higher mean age compared to those with low MDA levels (42.36 vs. 38.13 years). ROC analysis revealed that high MDA levels were a significant predictor of poor clinical outcomes in TBI patients with SAH, with an area under the curve of 0.714 ( Conclusion: Elevated serum MDA levels are a reliable biomarker for predicting poor clinical outcomes in patients with moderate to severe TBI complicated by SAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.